ALVION PRODUCTS
Explore our products
Developing and manufacturing noninfringing generic medicines in Europe.
Lenvatinib Capsules
Atorvastatin + Ezetimibe Film Coated Tablets
Rosuvastatin + EzetimibeFilm Coated Tablets
Ticagrelor Film Coated Tablets
Lenvatinib Capsules
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Lenvatinib | Capsules | 4 mg 10 mg | Renal cell carcinoma and Hepatocellular carcinoma | Lenvima® / Kisplyx® | Q3/2024 |
Atorvastatin + Ezetimibe Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Atorvastatin + Ezetimibe | Film Coated Tablets | 10mg+10mg 20mg+10mg 40mg+10mg 80mg+10mg | Cholesterol and triglyceride regulator | Atozet® | Completed |
Rosuvastatin + EzetimibeFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Rosuvastatin + Ezetimibe | Film Coated Tablets | 5mg+10mg 10mg+10mg 20mg+10mg 40mg+10mg | Cholesterol and triglyceride regulator | – | Launched |
Ticagrelor Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Ticagrelor | Film Coated Tablets | 60mg 90mg | Antithrombotic | Brilique® | Q1 2024 |
Ranolazine PRCapsules
RivaroxabanFilm Coated Tablets
Sitagliptin HydrochlorideFilm Coated Tablets
Sitagliptin Hydrochloride + MetforminFilm Coated Tablets
Ranolazine PRCapsules
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Ranolazine PR | Capsules | 350mg 500mg 750mg | Chronic Angina | Ranexa® | Completed |
RivaroxabanFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Rivaroxaban | Film Coated Tablets | 2.5mg 10mg 15mg20mg | Oral anticoagulant | Xarelto® | Completed |
Sitagliptin HydrochlorideFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Sitagliptin Hydrochloride | Film Coated Tablets | 25mg 50mg 100mg | Oral antidiabetic | Januvia® | Completed |
Sitagliptin Hydrochloride + MetforminFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Sitagliptin Hydrochloride + Metformin | Film Coated Tablets | 50mg+850mg 50mg+1000mg | Oral antidiabetic | Janumet® | Completed |
Mirabegron PRProlonged released f.c. tablets
Mirabegron + SolifenacinFilm Coated Tablets
ApixabanFilm Coated Tablets
ApixabanOral Solution
Mirabegron PRProlonged released f.c. tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Mirabegron PR | Prolonged released f.c. tablets | 25mg 50mg | Urinary antispasmodic | Betmiga® | Q42023 |
Mirabegron + SolifenacinFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Mirabegron + Solifenacin | Film Coated Tablets | 25mg+5mg 5mg+5mg | Urinary antispasmodic | Betmiga®/Vesicare® | Q22024 |
ApixabanFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Apixaban | Film Coated Tablets | 2.5mg 5mg | Oral anticoagulant | Eliquis® | Completed |
ApixabanOral Solution
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Apixaban | Oral Solution | 1mg/ml | Oral anticoagulant | Janumet® | Q22024 |
Vortioxetine Film Coated Tablets
Dapagliflozin Film Coated Tablets
Dapagliflozin + Metformin Film Coated Tablets
Dapagliflozin + Metformin XRFilm Coated Tablets
Vortioxetine Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Vortioxetine/td> | Film Coated Tablets | 5mg 10mg 20mg | Antidepressant | Brintellix® | Q22024 |
Dapagliflozin Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Dapagliflozin | Film Coated Tablets | 5mg 10mg | Oral antidiabetic | Forxiga® | Completed |
Dapagliflozin + Metformin Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Dapagliflozin + Metformin | Film Coated Tablets | 5mg+850mg 5mg+1000mg | Oral antidiabetic | Xigduo® | Q42023 |
Dapagliflozin + Metformin XRFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Dapagliflozin + Metformin XR | Film Coated Tablets | 5mg + 500mg 5mg + 1000mg 10mg + 500mg 10mg + 1000mg | Oral antidiabetic | XigduoXR® | Q1 2024 |
EmpagliflozinFilm Coated Tablets
Empagliflozin + Metformin Film Coated Tablets
LisdexamfetamineCapsules
EmpagliflozinFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Empagliflozin | Film Coated Tablets | 10mg 25mg | Oral antidiabetic | Jardiance® | Q3 2024 |
Empagliflozin + Metformin Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Empagliflozin + Metformin | Film Coated Tablets | 12.5mg+850mg 12.5mg+ 1000mg 5mg+850mg 5mg+1000mg | Oral antidiabetic | Synjardy® | Q42024 |
LisdexamfetamineCapsules
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Lisdexamfetamine | Capsules | 20mg30mg 40mg50mg 60mg 70mg | Attention deficit hyperactivity disorder (ADHD) | Vyvanse® | Q22024 |
